Immunoscore Refines CRC Prognosis, Therapy
-
By
January 7, 2026
-
4 min
The Immunoscore emerges as a superior method for predicting outcomes in colorectal cancer, exceeding traditional TNM staging by accurately identifying high-risk patients who could benefit from enhanced chemotherapy. Developed by researchers at The University of Hong Kong, the Immunoscore evaluates immune response through T-cell density in tumors. Despite large-scale validation proving its efficacy, its implementation in clinical practice is hindered by technical and cost-related barriers. The authors stress the need for its integration into standard care to improve patient treatment strategies.
1. Immunoscore predicts outcomes better than TNM staging in colorectal cancer.2. Key focus is on CD3+ and CD8+ T-cell densities.3. High Immunoscore patients benefit from chemotherapy.4. Low Immunoscore patients show limited chemotherapy benefit.5. Technical and cost barriers hinder Immunoscore implementation.6. The need for standardized training is critical.7. Prospective validation across diverse tumors is crucial for wider adoption.
Listen Tab content
